Pharmaceutical Technology® spoke with Dr. Weite Oldenziel, CEO of Ofichem, before CPHI Frankfurt 2025 to get his perspective ...

Regulatory scrutiny on traditional excipients like titanium dioxide and talc poses significant challenges, necessitating robust scientific evidence to address concerns. Sustainable practices in ...

State-of-the-art AI programs can support the development of drugs by predicting how proteins interact with small molecules.

Cambrex will invest $120M to expand U.S. drug manufacturing, boosting API capacity at its Iowa site and adding jobs amid ...

Picking a date for a press conference in Puerto Rico in the middle of hurricane season can be risky business. | Eli Lilly has ...

American Petroleum Institute CEO Mike Sommers joins 'Varney & Co.' to discuss how rising energy costs in New Jersey and Virginia are influencing the states’ gubernatorial races and fueling voter ...

VAI means objectionable conditions or practices were found, but the regulator is not prepared to take or recommend any administrative or regulatory action.

Throughout 2025, drugmakers of all stripes have collectively poured billions of dollars into U.S. manufacturing investments.

Next year will be the twentieth anniversary of a successful lawsuit against the state, “Myers v. Alaska Psychiatric Institute ...

NanoViricides, Inc. (NYSE American: NNVC ) (the "Company"), a clinical stage leader developing revolutionary broad-spectrum ...

India on Monday advanced an anti-dumping investigation into imports from China and Thailand of Ethambutol Hydrochloride, an ...

India imposes minimum import price (MIP) on Sulphadiazine API, restricting imports below Rs.1,774 per kg until September 30, 2026.